Company research
NeuBase Therapeutics, Inc.
CIK 1173281Updated Nov 16, 2026
Securities
Historical securities (1)
NBSE · NASDAQ · equity · closed May 11, 2024Name history
Ohr Pharmaceutical Inc · through Jul 12, 2019BBM HOLDINGS, INC. · through Aug 17, 2009PRIME RESOURCE INC · through Mar 23, 2007
NBSE price & chart
Historical security
This listing closed May 11, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
15-12G filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
EFFECT filing
EFFECT filing
15-12G filing
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 32,693,429Source | 64,167,593Source | 34,444,281Source | 12,531,397Source |
| Property, Plant and Equipment, NetUSD | 2,156,851Source | 2,463,882Source | 1,166,934Source | 430,995Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,152,663Source | 52,893,387Source | 31,992,283Source | 10,313,966Source |
| Assets, CurrentUSD | 24,648,665Source | 54,928,634Source | 32,808,540Source | 11,029,235Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,176,303Source | 1,536,186Source | 294,640Source | 265,686Source |
| Operating Lease, Right-of-Use AssetUSD | 5,614,698Source | 5,945,295Source | — | — |
| Other Assets, NoncurrentUSD | 0Source | 160,423Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,501,549Source | 10,097,820Source | 3,149,633Source | 2,502,013Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,300Source | 3,272Source | 2,315Source | 1,708Source |
| Additional Paid in CapitalUSD | 125,932,933Source | 123,034,404Source | 74,850,935Source | 37,027,875Source |
| Retained Earnings (Accumulated Deficit)USD | -102,744,353Source | -68,967,903Source | -43,558,602Source | -27,000,199Source |
| Stockholders' Equity Attributable to ParentUSD | 23,191,880Source | 54,069,773Source | 31,294,648Source | 10,029,384Source |
| Liabilities and EquityUSD | 32,693,429Source | 64,167,593Source | 34,444,281Source | 12,531,397Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,166,385Source | 4,194,224Source | — | 2,502,013Source |
| Operating Lease, Liability, CurrentUSD | 553,066Source | 382,576Source | — | — |
| Accounts Payable, CurrentUSD | 1,843,027Source | 1,807,885Source | 1,505,042Source | 1,477,152Source |
| Operating Lease, Liability, NoncurrentUSD | 5,335,164Source | 5,794,096Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,662,660Source | 1,747,746Source | 555,883Source | 405,599Source |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 800,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,897,689Source | 3,696,384Source | 5,194,784Source | 9,785,083Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 35,142Source | 294,548Source | -129,088Source | 962,434Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,011,966Source | -18,873,684Source | -10,710,071Source | -2,845,488Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 1,100,040Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -471,741Source | -2,563,467Source | -716,820Source | -685,225Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 471,711Source | 1,438,415Source | 716,820Source | 455,200Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 0Source | 14Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -257,017Source | 42,338,255Source | 33,105,208Source | 13,595,079Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -29,740,724Source | 20,901,104Source | 21,678,317Source | 10,064,366Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 23,152,663Source | — | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 3,244Source | 3,177Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | 0Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,897,689Source | 3,696,384Source | 5,194,784Source | 9,785,083Source |
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 104,000Source |
| DepreciationUSD | — | 400,000Source | 100,000Source | 24,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 0Source | 316,724Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -11,439Source | -31,853Source | -3,230Source | — |
| General and Administrative ExpenseUSD | 11,869,747Source | 12,202,217Source | 10,123,298Source | 9,095,674Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -415,747Source | -224,534Source | -262,861Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,776,450Source | -25,409,301Source | -17,384,520Source | -26,958,247Source |
| Nonoperating Income (Expense)USD | -458,111Source | — | — | — |
| Operating ExpensesUSD | 33,318,339Source | 26,565,447Source | 17,069,306Source | 26,336,407Source |
| Other Nonoperating Income (Expense)USD | -166,873Source | 1,156,146Source | -315,214Source | — |
| Payments for Repurchase of WarrantsUSD | — | — | 0Source | 141,864Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 42,616,376Source | 33,283,970Source | 8,268,157Source |
| Proceeds from Stock Options ExercisedUSD | 868Source | 112,446Source | 171,030Source | — |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -33,318,339Source | -26,565,447Source | -17,069,306Source | -26,336,407Source |
| Other Nonoperating Income (Expense)USD | -166,873Source | 1,156,146Source | -315,214Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,776,450Source | -25,409,301Source | -17,384,520Source | -26,958,247Source |
| Earnings Per Share, BasicUSD per share | -1.04Source | -0.93Source | — | — |
| Earnings Per Share, DilutedUSD per share | -1.04Source | -0.93Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 32,487,244Source | 27,306,043Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 32,487,244Source | 27,306,043Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 104,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 767,302Source | 403,043Source | 280,463Source | 128,372Source |
| General and Administrative ExpenseUSD | 11,869,747Source | 12,202,217Source | 10,123,298Source | 9,095,674Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -415,747Source | -224,534Source | -262,861Source | — |
| Interest ExpenseUSD | 24,047Source | 32,330Source | 7,686Source | 128,951Source |
| Interest Income, OtherUSD | 148,556Source | 12,550Source | — | — |
| Nonoperating Income (Expense)USD | -458,111Source | — | — | — |
| Operating ExpensesUSD | 33,318,339Source | 26,565,447Source | 17,069,306Source | 26,336,407Source |
| Other ExpensesUSD | — | — | — | 621,840Source |
| Other IncomeUSD | — | 450,309Source | 412,371Source | — |
| Research and Development ExpenseUSD | 21,448,592Source | 11,475,201Source | 6,946,008Source | 4,273,318Source |